Duofemme

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Duofemme

Quick Facts

Property Description
Active Ingredients Estradiol (Estrogen), Norethisterone (Progestogen)
Form Film-coated tablets
Pharmacological Class Sex Hormone Combination, Hormone Replacement Therapy
Common Use Postmenopausal hormonal support
Origin Semi-synthetic/Derived

What is Duofemme?

Duofemme is a prescription-only medication classified as a Combined Hormone Replacement Therapy (HRT), intended for women who are postmenopausal and still have their uterus. It is administered via the oral route as a film-coated tablet to provide systemic hormonal support and management.

What Type of Medicine is Duofemme?

Duofemme is classified as a Sex hormone combination within the broader Hormone Replacement Therapy class. It is a combination product containing both an estrogen and a progestogen, making it specifically suitable for postmenopausal women with an intact uterus. This dual-hormone structure is clinically recognized to be necessary for patient safety regarding the uterine lining.

Composition: Estradiol, Norethisterone, and Form

The efficacy of Duofemme is driven by its two active ingredients: Estradiol and Norethisterone. Estradiol is the principal estrogen component, structurally mirroring the body's natural hormone. Norethisterone is a synthetic progestogen that mimics the effects of endogenous progesterone. This specific pairing of a natural-like estrogen and a synthetic progestogen is a key feature of the Duofemme combination, ensuring a balanced hormonal effect. The medicine is prepared as a solid film-coated tablet designed for oral administration.

How Does Duofemme Relate to Hormone Balance?

The core goal of Duofemme is hormone restoration, aimed at compensating for reduced hormone levels following menopause. This is achieved by simultaneously using estradiol for fundamental support and norethisterone acetate for crucial endometrial protection. This combined approach is the integral therapeutic strategy, providing foundational hormonal support to women after menopause while maintaining systemic hormonal balance.

Regulatory References

  1. National Institutes of Health (NIH) DailyMed

What side effects are possible with Duofemme?

Possible Side Effects and Safety Information

The official regulatory profile for Duofemme (Estradiol/Norethisterone combination) details potential adverse reactions categorized by frequency and affected body system, strictly based on government-approved labeling.

Frequency-Classified Adverse Reactions

The product information uses standard classifications for frequency:

Classification Examples of Reactions
Very Common (ge 1/10) Headache, Breast tenderness or pain, Menstrual-like bleeding/Spotting.
Common (ge 1/100 to < 1/10) Nausea, Abdominal pain, Dizziness, Edema (fluid retention), Rash, Weight increase.
Uncommon (ge 1/1,000 to < 1/100) Hypersensitivity reactions, Migraine, Thrombophlebitis.

Adverse effects are documented across various System-Organ Classes, including Reproductive system and breast disorders, Nervous system disorders, and Gastrointestinal disorders.

Serious Adverse Reactions and Safety Constraints

The regulatory safety notes define clinically significant, though less frequent, risks. These serious adverse reactions include Venous Thromboembolism (VTE), Pulmonary Embolism, Stroke, and Myocardial Infarction. The labeling also documents an increased incidence of certain hormone-sensitive malignancies, such as Breast and Endometrial cancer.

Safety notes tied to treatment duration specify that bleeding irregularities are officially more common during the initial months of treatment. Conversely, the risk for serious cardiovascular events is associated with prolonged use (long-term exposure).

Use is officially restricted in individuals with conditions such as active or severe hepatic impairment and a history of or current VTE or undiagnosed vaginal bleeding, as defined by regulatory authorities.

Overdose and Emergency Response

Documented Overdose Manifestations

Acute oral overdose of the estradiol and norethisterone combination is formally documented to result in an exaggeration of expected hormonal effects. The most common symptoms reported in regulatory summaries are nausea, vomiting, and abdominal pain. Breast tenderness is also listed as a potential manifestation. A specific regulatory finding is withdrawal bleeding, which may occur several days after the cessation of the high dose exposure. No acute life-threatening outcomes are explicitly listed as direct consequences of overdose in the regulatory overdose sections.

Required Emergency Actions

Immediate medical attention must be sought if an overdose is suspected or if severe symptoms develop. The official management requires the discontinuation of therapy. Treatment is strictly symptomatic and supportive, as no specific antidote is known for this hormonal combination. The patient must be clinically monitored to manage any adverse reactions that may arise. Regulatory information states that the extent to which the active ingredients may be removed by procedures such as hemodialysis is unknown.

Therapeutic Uses of Duofemme

What Duofemme Treats: Main Uses and Benefits

Duofemme is a prescription medicine commonly used to provide supportive therapeutic relief by addressing the primary discomforts and long-term consequences of low hormone levels following menopause. The medication is applied across domains where additional symptomatic support is needed, used in areas where short-term symptom management is appropriate (hot flushes and night sweats), is applied in addressing symptoms related to inflammatory or irritative states (such as dryness and irritation), and is considered relevant in conditions where functional stability becomes affected (Bone Health) in high-risk women.

Combinations of estrogen and progestin are used to treat certain menopausal symptoms and prevent bone thinning.

The medication is relevant for easing symptoms that interfere with daily functioning, such as those that become intense or disruptive, and is applied in addressing symptom clusters that may become pronounced.

“This combined hormonal support may assist with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.”

By providing symptomatic assistance, Duofemme helps ease the overall symptom burden and supports general well-being during symptomatic phases of the postmenopausal experience.

Quick Fact
Relief for Vasomotor Symptoms (Hot Flushes, Night Sweats)
Support for Urogenital Comfort (Dryness, Irritation)
Long-Term Focus Skeletal Health Maintenance (Osteoporosis Prevention)

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Duofemme?

Eligibility for Duofemme, a combination Hormone Replacement Therapy (HRT), is strictly defined by regulatory documents, focusing primarily on patient population and pre-existing medical conditions.

Approved Population and Exclusions

Duofemme is officially intended only for postmenopausal women who have an intact uterus. Use is not indicated for the pediatric population (children and adolescents), and therapy is strictly contraindicated during pregnancy and lactation.

Absolute Contraindications

Regulatory labeling prohibits the use of Duofemme in individuals with specific health histories:

  • Known, suspected, or past history of breast cancer or other estrogen-dependent malignant tumors.
  • Active or previous thromboembolic disorders (e.g., DVT, stroke, or heart attack) or diagnosed thrombophilic conditions.
  • Acute liver disease or uncorrected abnormal liver function test results.
  • Undiagnosed abnormal genital bleeding or untreated endometrial hyperplasia.

Restricted Use and Caution

Use requires close clinical observation and caution in patients with underlying conditions such as severe cardiac or renal dysfunction due to the risk of fluid retention, as well as in women with pre-existing hypertriglyceridaemia. Limited experience and specific caution are advised when initiating treatment in older adults over 65 years of age.

What should I know about interactions with other medicines?

This section outlines known and predicted interactions for Duofemme (conjugated estrogens/bazedoxifene) based on regulatory information.

Restrictions and Contraindicated Combinations

It is advised that women taking this medication should not take other products containing progestins, additional estrogens, or additional estrogen agonist/antagonists. The co-administration of these substance categories is a key restriction.

Pharmacokinetic Interaction Mechanisms

The components of Duofemme are metabolized by specific liver enzyme systems, making them susceptible to drug-drug interactions with agents that affect these systems:

  • Enzyme Inhibitors: Drugs that strongly inhibit Cytochrome P450 CYP3A4 are expected to increase the level of the conjugated estrogens component. Separately, drugs that inhibit Uridine Diphosphate Glucuronosyltransferase (UGT), particularly UGT1A1 and UGT1A4, are expected to increase the plasma concentration of bazedoxifene.
  • Enzyme Inducers: Drugs that strongly induce CYP3A4 or UGT enzymes are expected to decrease the plasma levels of the components, potentially reducing the desired therapeutic effect.

Specific Interacting Products

  • Statins: Co-administration with atorvastatin has been shown to significantly increase the exposure (Cmax and AUC) of bazedoxifene.
  • Food: Concomitant use with grapefruit or grapefruit juice should be avoided as it may alter the drug's amount in the body.

These interactions are categorized as clinically significant, necessitating careful evaluation by a healthcare provider.

Mechanism of Action

How Duofemme Works

Dual Hormone Receptor Agonism

Duofemme's mechanism is based on dual hormone receptor agonism. Its two active components function as agonists, directly activating specific nuclear hormone receptors—Estrogen Receptor (ER) and Progesterone Receptor (PR)—across various target cells. Binding to these receptors initiates a cascade that alters gene transcription, leading to modified protein synthesis and changes in cellular function in tissues like the uterus and bone.


Pathway Modulation

In the uterus, the estrogenic component drives cell proliferation in the endometrium. This is subsequently balanced by the progestin component, which induces cell differentiation and stabilization. This precisely timed modulation results in the sequential turnover of tissue. Concurrently, the mechanism acts on the skeletal homeostatic pathway by influencing the balance between bone-resorbing osteoclasts and bone-forming osteoblasts. Limiting osteoclast activity is a direct consequence that results in a net influence on bone mineral content.

Dosage and Administration Information

How to Use Duofemme

Duofemme is prescribed for oral administration only and is used in a continuous sequential regimen, which means the daily dosing is uninterrupted, but the hormonal composition changes cyclically. The entire sequence is managed through a specific 28-day cycle with two distinct types of film-coated tablets.


Official Dosing Schedule

Cycle Phase Tablet Composition Duration
Estrogen-Only Red tablet (Estradiol 1 mg) First 16 days
Combination White tablet (Estradiol 1 mg / Norethisterone Acetate 1 mg) Following 12 days

Administration Protocol

The standard regimen is one tablet taken daily at approximately the same time each day to maintain consistent hormone levels. Tablets can be taken with or without food and drink.

Upon completing the 28-day pack, treatment is continued immediately with the first red tablet of a new pack, thereby establishing a continuous cycle. A menstruation-like withdrawal bleeding is generally expected at the start of each new treatment cycle.

Handling Missed Doses

If a dose is missed, the tablet should be taken as soon as possible within 12 hours of the usual time. If more than 12 hours have passed, the missed tablet must be discarded, and the next dose should be taken at the regular time. A double dose should never be taken to make up for a missed one.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Duofemme

Evidence for Vasomotor Symptoms (Hot Flushes and Night Sweats)

The evidence supporting the combination therapy was studied in research exploring how symptoms change over time in postmenopausal women with an intact uterus. These studies are primarily short-term, prospective Randomized Controlled Trials (RCTs) compared against placebo. These studies monitored outcomes related to physical discomfort, specifically measuring the daily frequency and average severity of the hot flushes, as relevant in trials assessing short-term or episodic symptom patterns.

Findings describe patterns observed in the studies, and research highlights changes measured during the study period related to symptom intensity. The follow-up durations for primary efficacy were typically limited to between 12 and 24 weeks, meaning there is limited information for long-term outcomes.

Evidence for Bone Health and Maintenance

The combination was evaluated in research contexts and was studied for outcomes related to systemic or functional imbalance, specifically the postmenopausal bone loss. Research was conducted using RCTs and meta-analyses over intermediate time intervals, typically ranging from one to two years. The research examined outcomes related to the absolute change in Bone Mineral Density (BMD) at critical areas like the lumbar spine and hip.

The longest-term data on fracture incidence often comes from the broader HRT class data, rather than being fully established for this exact combination. Follow-up durations were limited in specific trials, and the full, long-term data on bone stability are not fully established.

Evidence in Specific Populations and Research Gaps

Research has also explored outcomes related to Metabolic Markers like Fasting Glucose and Insulin levels, although data show patterns related to these markers, findings were mixed across previous studies, meaning that certainty remains low for outcomes related to systemic or functional imbalance. Furthermore, data for certain groups, such as specific subgroups of women based on age or symptom presentation, remain insufficient, and comparative evidence against all other therapeutic options is also lacking. Research is ongoing to address these gaps and further contextualize the findings.

Frequently Asked Questions (FAQ)

Common questions about Duofemme (FAQ)


Q: What are the general expectations for the benefits and outcomes of Duofemme?

A: According to official documents, the general expectations for Duofemme are related to two main areas. Research indicates that relief of common postmenopausal symptoms, such as hot flushes, may begin during the first few weeks of use. The medication is also described in official documents as influencing the balance of bone mineral content.


Q: How long does it usually take before the effects of Duofemme become noticeable?

A: Official product information and clinical studies suggest that the onset of effects is typically observed early in the course of therapy. Research indicates that statistically significant changes in hot flushes may be observed after approximately three weeks of use.


Q: How long do people typically remain on Duofemme therapy?

A: Regulatory guidance for Hormone Replacement Therapy (HRT) emphasizes that treatment should be managed carefully. Regulatory guidance emphasizes that the use of HRT should be assessed periodically to ensure the continued benefit justifies the risk.


Q: Does Duofemme interact with herbal supplements like St. John's Wort?

A: Yes, official documents for this class of medicine specifically note the potential for interaction with certain herbal products. St. John’s Wort is cited as a supplement that has the potential to decrease the blood levels of the hormone components of Duofemme. This happens because St. John's Wort can affect the liver enzymes that process the medication.


Q: What percentage of patients reported improvement in the clinical studies for Duofemme?

A: Regulatory summaries of clinical trials focus on the findings of efficacy rather than specific patient percentages. Studies observed that the medication resulted in a measured reduction in the severity and number of symptoms compared to a placebo. Detailed patient response rates, including exact percentages, are typically found within the full clinical study reports, which are more technical documents.


Q: Is it common to feel unusually tired or fatigued when first starting Duofemme?

A: Fatigue is listed in the medication’s safety profile as a possible side effect. While the official documentation does not categorize it by specific frequency, it is a reported experience.


Q: Can Duofemme affect mood, anxiety, or mental health?

A: Yes, the official side effect profile includes various psychological and mood-related reactions. These effects, categorized as psychiatric disorders, include experiences like insomnia, anxiety, irritability, and feelings of depression or general mood disturbances.


Q: Can people who drink alcohol use Duofemme?

A: Official regulatory information advises caution regarding the use of alcohol. Regulatory information suggests that the use of alcohol with this type of medicine has the potential to increase the risk of adverse effects.


Q: Can I take Duofemme if I am currently trying to become pregnant?

A: The medication is strictly reserved for postmenopausal women and is not indicated for women of childbearing age. Official documents state that Duofemme is absolutely contraindicated (must not be used) during pregnancy. Official regulatory warnings advise against its use while attempting to conceive.


Q: Does Duofemme have a risk of dependency or withdrawal if stopped?

A: Official documentation does not report a risk of dependency associated with Duofemme use. However, when treatment cycles are concluded or interrupted, the body’s hormonal change typically leads to an anticipated event known as withdrawal bleeding.


Q: What happens if I stop taking Duofemme suddenly?

A: Stopping the medication suddenly may lead to changes in your bleeding pattern. According to product information, this sudden interruption may result in unscheduled withdrawal bleeding or spotting. Official guidance related to missed doses instructs that a missed tablet should be discarded rather than doubling up or taking it late.


Q: Is Duofemme known to affect sleep patterns?

A: Yes, the official safety profile notes that sleep difficulties may be experienced. The category of side effects related to mood and mental health includes reports of insomnia, which is defined as persistent trouble sleeping.


Q: Can Duofemme interact with medications for high blood pressure?

A: Official warnings note that Hormone Replacement Therapy (HRT) may cause an increase in blood pressure. Because of this potential effect, regulatory information indicates that patients with existing high blood pressure (hypertension) may need closer observation while using Duofemme.


Q: Does Duofemme have a known impact on fertility?

A: Duofemme is prescribed exclusively for postmenopausal women and is not intended to treat fertility issues. For individuals who still possess reproductive potential, official information for similar medicines indicates that the function of ovulation will return rapidly after treatment is discontinued.


Q: What is the meaning of the half-life of Duofemme?

A: The term 'half-life' is used in pharmacokinetics to describe how quickly a drug is processed by the body. Specifically, it is the time required for half of the medicine to be cleared from the bloodstream. For the active components of Duofemme, the half-life is typically reported in the range of 2 to 11 hours.

How should Duofemme be stored and disposed of?

How to Store and Dispose of Duofemme? — Official Regulatory Information

Storage and Disposal Scope Official Labeled Requirements
Labeled Storage Temperature Do not store above 25°C.
Light/Moisture Protection Keep the container in the outer carton to protect the product from light.
Handling Requirements Do not refrigerate. Use before the expiry date stated on the label.
Child-Protection Keep this medicine out of the sight and reach of children.
Disposal Instructions Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use.

These official regulatory statements define the mandatory environmental controls for Duofemme, ensuring product stability and integrity are maintained. The required storage conditions explicitly prohibit refrigeration and mandate a maximum temperature threshold. Compliance with these rules, along with the required return of unused medicine to a pharmacist, adheres to the regulated end-of-life process and environmental protection standards.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Duofemme found in:

A-Z Index: